Author
Kutti Sridharan, GurusaravananKotagiri, Rajesh
Chandiramani, Vijay H
Mohan, Babu P
Vegunta, Rathnamitreyee
Vegunta, Radhakrishna
Rokkam, Venkata R P
Affiliation
Univ Arizona, Banner Univ Med Ctr, Dept Internal MedIssue Date
2020-07
Metadata
Show full item recordPublisher
LIPPINCOTT WILLIAMS & WILKINSCitation
Sridharan, G. K., Kotagiri, R., Chandiramani, V. H., Mohan, B. P., Vegunta, R., Vegunta, R., & Rokkam, V. R. (2020). COVID-19 and avoiding ibuprofen. How good is the evidence?. American journal of therapeutics, 27(4), e400-e402.Journal
AMERICAN JOURNAL OF THERAPEUTICSRights
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Ibuprofen is an over-the-counter medication that is used widely for the treatment of pain and fever during COVID-19 pandemic. A concern was raised regarding the safety of ibuprofen use because of its role in increasing ACE2 levels within the Renin-Angiotensin-Aldosterone system. ACE2 is the coreceptor for the entry of SARS-CoV-2 into cells, and so, a potential increased risk of contracting COVID-19 disease and/or worsening of COVID-19 infection was feared with ibuprofen use. However, available data from limited studies show administration of recombinant ACE2 improves lung damage caused by respiratory viruses, suggesting ibuprofen use may be beneficial in COVID-19 disease. At this time, there is no supporting evidence to discourage the use of ibuprofen.Note
No embargo COVID-19ISSN
1075-2765EISSN
1536-3686PubMed ID
32366740Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1097/MJT.0000000000001196
